# Giles Best

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8466755/publications.pdf

Version: 2024-02-01

| 103 | 1,312 | 471509 | 414414 |
|---|---|---|---|
| papers | citations | 17 h-index | 32 g-index |

| 107 | 107 | 107 | 1992 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica, 2010, 95, 1705-1712. | 3.5 | 116 |
| 2 | Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples. Journal of Extracellular Vesicles, 2016, 5, 25355. | 12.2 | 96 |
| 3 | Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 99-104. | 1.3 | 89 |
| 4 | A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia, 2009, 23, 212-214. | 7.2 | 87 |
| 5 | CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leukemia Research, 2011, 35, 750-756. | 0.8 | 60 |
| 6 | A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia, 2008, 22, 1456-1459. | 7.2 | 59 |
| 7 | Oxygenâ€evoked Na + transport in rat fetal distal lung epithelial cells. Journal of Physiology, 2001, 532, 105-113. | 2.9 | 58 |
| 8 | Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatmentâ€free and overall survival in Chronic Lymphocytic Leukaemia. British Journal of Haematology, 2018, 181, 97-101. | 2.5 | 36 |
| 9 | ZAP-70 by flow cytometry: A comparison of different antibodies, anticoagulants, and methods of analysis. Cytometry Part B - Clinical Cytometry, 2006, 70B, 235-241. | 1.5 | 32 |
| 10 | Inhibition of Protein Kinase CK2 Closes the CFTR Cl<sup>-</sup> Channel, but has no Effect on the Cystic Fibrosis Mutant Î”F508-CFTR. Cellular Physiology and Biochemistry, 2009, 24, 347-360. | 1.6 | 32 |
| 11 | DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia. Leukemia, 2014, 28, 787-793. | 7.2 | 31 |
| 12 | Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia and Lymphoma, 2014, 55, 2085-2092. | 1.3 | 29 |
| 13 | ZAP-70 in B cell malignancies. Leukemia and Lymphoma, 2005, 46, 1689-1698. | 1.3 | 26 |
| 14 | <scp>MEK</scp>1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and <scp>ABT</scp>â€737 under conditions that mimic the chronic lymphocytic leukaemia (<scp>CLL</scp>) tumour microenvironment. British Journal of Haematology, 2018, 182, 360-372. | 2.5 | 23 |
| 15 | A novel physical and functional association between nucleoside diphosphate kinase A and AMP-activated protein kinase Î±1 in liver and lung. Biochemical Journal, 2005, 392, 201-209. | 3.7 | 22 |
| 16 | Prognostic Factors in the UK LRF CLL4 Trial.. Blood, 2005, 106, 2099-2099. | 1.4 | 20 |
| 17 | Modeling the chronic lymphocytic leukemia microenvironmentin vitro. Leukemia and Lymphoma, 2017, 58, 266-279. | 1.3 | 18 |
| 18 | Immune failure, infection and survival in chronic lymphocytic leukemia. Haematologica, 2018, 103, e329-e329. | 3.5 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Importance of between and within Subject Variability in Extracellular Vesicle Abundance and Cargo when Performing Biomarker Analyses. Cells, 2021, 10, 485. | 4.1 | 18 |
| 20 | Chronic lymphocytic leukaemia, monoclonal <scp>B</scp>â€lymphocytosis and pregnancy: five cases, a literature review and discussion of management. British Journal of Haematology, 2015, 168, 350-360. | 2.5 | 17 |
| 21 | The phosphorylation status of membrane-bound nucleoside diphosphate kinase in epithelia and the role of AMP. Molecular and Cellular Biochemistry, 2009, 329, 107-114. | 3.1 | 15 |
| 22 | The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. Leukemia and Lymphoma, 2015, 56, 3407-3417. | 1.3 | 15 |
| 23 | Assessing cross-reactivity to neuromuscular blocking agents by skin and basophil activation tests in patients with neuromuscular blocking agent anaphylaxis. British Journal of Anaesthesia, 2019, 123, e144-e150. | 3.4 | 15 |
| 24 | Integrating basophil activation tests into evaluation of perioperative anaphylaxis to neuromuscular blocking agents. British Journal of Anaesthesia, 2019, 123, e135-e143. | 3.4 | 15 |
| 25 | Prognostic Factors in the UK LRF CLL4 Trial.. Blood, 2006, 108, 299-299. | 1.4 | 14 |
| 26 | Oxygen-evoked changes in transcriptional activity of the 5â€²-flanking region of the human amiloride-sensitive sodium channel (Î±ENaC) gene: role of nuclear factor IºB. Biochemical Journal, 2002, 364, 537-545. | 3.7 | 13 |
| 27 | Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype. Leukemia and Lymphoma, 2012, 53, 2314-2320. | 1.3 | 13 |
| 28 | Mechanisms of Action of Fludarabine Nucleoside Against Human Raji Lymphoma Cells. Nucleosides, Nucleotides and Nucleic Acids, 2014, 33, 375-383. | 1.1 | 13 |
| 29 | Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells. Leukemia and Lymphoma, 2018, 59, 2917-2928. | 1.3 | 13 |
| 30 | A Randomised Dose De-Escalation Study of Oral Fludarabine, Â±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged â‰¥65 Years: Final Analysis of Response and Toxicity. Blood, 2014, 124, 3325-3325. | 1.4 | 13 |
| 31 | Protein Kinase CK2, Cystic Fibrosis Transmembrane Conductance Regulator, and the Î”F508 Mutation. Journal of Biological Chemistry, 2007, 282, 10804-10813. | 3.4 | 12 |
| 32 | The novel Hspâ€90 inhibitor SNX7081 is significantly more potent than 17â€AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway. British Journal of Haematology, 2010, 151, 185-188. | 2.5 | 12 |
| 33 | The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leukemia and Lymphoma, 2012, 53, 1367-1375. | 1.3 | 12 |
| 34 | The dual inhibitor of the phosphoinositolâ€3 and PIM kinases, IBLâ€202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. British Journal of Haematology, 2018, 182, 654-669. | 2.5 | 12 |
| 35 | Molecular pathogenesis of chronic lymphocytic leukaemia. British Journal of Haematology, 2019, 186, 668-684. | 2.5 | 12 |
| 36 | Hsp90 Inhibitor SNX-7081 Dysregulates Proteins Involved with DNA Repair and Replication and the Cell Cycle in Human Chronic Lymphocytic Leukemia (CLL) Cells. Journal of Proteome Research, 2013, 12, 1710-1722. | 3.7 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Surface profiles for subclassification of chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 1046-1056. | 1.3 | 10 |
| 38 | Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. EJHaem, 2022, 3, 129-138. | 1.0 | 10 |
| 39 | The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia. Oncotarget, 2015, 6, 40981-40997. | 1.8 | 9 |
| 40 | Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia and Lymphoma, 2016, 57, 1033-1043. | 1.3 | 8 |
| 41 | Lymphoma cellâ€ofâ€“origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts. British Journal of Haematology, 2018, 181, 272-275. | 2.5 | 8 |
| 42 | Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment. Leukemia and Lymphoma, 2018, 59, 1927-1937. | 1.3 | 8 |
| 43 | Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date. World Journal of Clinical Cases, 2015, 3, 694. | 0.8 | 8 |
| 44 | Transglutaminase 2 and nucleoside diphosphate kinase activity are correlated in epithelial membranes and are abnormal in cystic fibrosis. FEBS Letters, 2009, 583, 2789-2792. | 2.8 | 7 |
| 45 | Fludarabine Nucleoside Modulates Nuclear â€œSurvival and Deathâ€•Proteins in Resistant Chronic Lymphocytic Leukemia Cells. Nucleosides, Nucleotides and Nucleic Acids, 2011, 30, 1181-1189. | 1.1 | 7 |
| 46 | Type C <scp>TP</scp>53â€‹<scp>CDKN</scp>1A pathway dysfunction occurs independently of <scp>CDKN</scp>1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with <scp>TP</scp>53 abnormalities. British Journal of Haematology, 2017, 178, 824-826. | 2.5 | 7 |
| 47 | Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment. Leukemia and Lymphoma, 2019, 60, 1632-1643. | 1.3 | 7 |
| 48 | Microbial disruption in the gut promotes cerebral endothelial dysfunction. Physiological Reports, 2021, 9, e15100. | 1.7 | 7 |
| 49 | Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human <scp>B</scp>â€‹lymphoid cell lines, with cytosolic and mitochondrial increases in p53. Proteomics - Clinical Applications, 2012, 6, 279-290. | 1.6 | 6 |
| 50 | The clinical significance of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukaemia (CLL). Scandinavian Journal of Infectious Diseases, 2013, 45, 729-729. | 1.5 | 6 |
| 51 | Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2020, 61, 1810-1822. | 1.3 | 6 |
| 52 | A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, Â±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged â‰¥65 Years â€“ End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. Blood, 2012, 120, 436-436. | 1.4 | 6 |
| 53 | Profiles of Surface Mosaics on Chronic Lymphocytic Leukemias Distinguish Stable and Progressive Subtypes. Journal of Pharmacy and Pharmaceutical Sciences, 2013, 16, 231. | 2.1 | 5 |
| 54 | Expression of Intracellular Reactive Oxygen Species in Hematopoietic Stem Cells Correlates with Time to Neutrophil and Platelet Engraftment in Patients Undergoing Autologous Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1997-2002. | 2.0 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 4695-4695. | 1.4 | 5 |
| 56 | Lipid uptake in chronic lymphocytic leukemia. Experimental Hematology, 2022, 106, 58-67. | 0.4 | 5 |
| 57 | The Precursor of Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2009, 360, 2575-2576. | 27.0 | 4 |
| 58 | Diagnostic techniques and therapeutic challenges in patients withTP53dysfunctional chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 2105-2115. | 1.3 | 4 |
| 59 | Assessing pilot vial material as a surrogate for functional and phenotypic stem cell markers in cryopreserved haematopoietic stem cell product. Bone Marrow Transplantation, 2016, 51, 1631-1632. | 2.4 | 4 |
| 60 | Surface Profiling of Extracellular Vesicles from Plasma or Ascites Fluid Using DotScan Antibody Microarrays. Methods in Molecular Biology, 2017, 1619, 263-301. | 0.9 | 4 |
| 61 | IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. Blood Advances, 2020, 4, 5093-5106. | 5.2 | 4 |
| 62 | The ClpP activator ONCâ€212 (TRâ€31) inhibits BCL2 and Bâ€cell receptor signaling in CLL. EJHaem, 2021, 2, 81-93. | 1.0 | 4 |
| 63 | Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment. Blood, 2019, 134, 5443-5443. | 1.4 | 4 |
| 64 | The Safety and Tolerability of Oral Fludarabine, Â±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged â‰¥65 Years â€“ Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study.. Blood, 2010, 116, 699-699. | 1.4 | 4 |
| 65 | Monoclonal B-lymphocytosis in patients aged over 90 years is common but not inevitable, and has a prevalence comparable to that in individuals aged 65â€“90 years. Leukemia and Lymphoma, 2015, 56, 2182-2184. | 1.3 | 3 |
| 66 | Serum from a subset of patients with chronic lymphocytic leukemia and large local reactions to mosquito bites induces upregulation of CD63 surface expression on basophils in atopic donors. Leukemia and Lymphoma, 2016, 57, 2417-2420. | 1.3 | 3 |
| 67 | The future of laboratory testing in chronic lymphocytic leukaemia. Pathology, 2021, 53, 377-384. | 0.6 | 3 |
| 68 | MEK1/2 Inhibition By MEK162 Is Effective Against Chronic Lymphocytic Leukaemia Cells Under Conditions That Mimic Stimulation of B-Cell Receptor-Mediated Signaling. Blood, 2014, 124, 3330-3330. | 1.4 | 3 |
| 69 | The phosphoinositide 3-kinase pathway in chronic lymphocytic leukemia: evidence for phosphatase and tensin homolog deletion on chromosome 10 deregulation. Leukemia and Lymphoma, 2013, 54, 1123-1124. | 1.3 | 2 |
| 70 | Protein kinase C isoform expression in chronic lymphocytic leukemia: a potential target for therapy?. Leukemia and Lymphoma, 2013, 54, 2098-2099. | 1.3 | 2 |
| 71 | Insight into del17p lowâ€frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial. British Journal of Haematology, 2021, 193, 556-560. | 2.5 | 2 |
| 72 | The Oxazolidinone Derivative Locostatin Induces Apoptosis in CLL Cells through Inhibition of AKT and MAPK-ERK1/2 Signaling Under Conditions That Mimic the Tumor Microenvironment. Blood, 2014, 124, 3326-3326. | 1.4 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | ZAP-70 by Flow Cytometry: Comparison of Methodologies, and with IgVH Mutational and ZAP-70 Methylation Status.. Blood, 2005, 106, 1181-1181. | 1.4 | 2 |
| 74 | Protein kinase CK2, cystic fibrosis transmembrane conductance regulator, and the deltaF508 mutation: F508 deletion disrupts a kinase-binding site. Journal of Biological Chemistry, 2008, 283, 25103. | 3.4 | 2 |
| 75 | 5.25 Safety and Tolerability of Oral Fludarabine, with or without Oral Cyclophosphamide and Intravenous Rituximab Therapy, in Previously Untreated Patients with Chronic Lymphocytic Leukaemia Aged 65 Years or Older: Second Interim Analysis from the Australasian Leukaemia and Lymphoma Group and CLL Australian Research Consortium CLL5 Study. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S259-S260. | 0.4 | 1 |
| 76 | Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2020, 61, 3165-3176. | 1.3 | 1 |
| 77 | A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression. British Journal of Haematology, 2021, 192, e77-e81. | 2.5 | 1 |
| 78 | The Hsp90 Inhibitor SNX7081 Restores the Fludarabine Sensitivity of Chronic Lymphocytic Leukemia (CLL) Cells Harbouring Mutations of ATM or TP53. Blood, 2010, 116, 2473-2473. | 1.4 | 1 |
| 79 | Detailed Long-Term Follow up of Treatment-Naive Chronic Lymphocytic Leukemia (CLL) Patients in the Australasian Leukemia and Lymphoma Group (ALLG) CLL5 Trial; Data on 17 (15% of Total Cohort) Patients from a Single-Institution. Blood, 2015, 126, 5294-5294. | 1.4 | 1 |
| 80 | 2.19 Fludarabine-Induced Changes in p63 and p73 Expression and TP53 Protein Binding in TP53 Wild-Type and Mutated Cell Lines. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S171. | 0.4 | 0 |
| 81 | 4.7 Identification of Novel Protein Markers of Progressive Chronic Lymphocytic Leukaemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S221-S222. | 0.4 | 0 |
| 82 | 4.21 Functional Categorisation of Tumour Cell p53/p21 Responses to Etoposide and Nutlin3a Exposure Correlates with Bi-allelic ATM Lesions and Mono- or Bi-allelic Lesions of TP53 in Chronic Lymphocytic Leukaemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S231-S233. | 0.4 | 0 |
| 83 | 5.26 Hsp90 Inhibitor Restores P53-Mutated MEC1 Chronic Lymphocytic Leukemia Cell Sensitivity to Fludarabine by Downregulating DNA Repair and Endoplasmic Reticulum Chaperone Proteins. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S260-S261. | 0.4 | 0 |
| 84 | Profiling the Lipid Raft Proteome from Human MEC1 Chronic Lymphocytic Leukemia Cells. Journal of Proteomics and Bioinformatics, 2014, 07, . | 0.4 | 0 |
| 85 | Serum from a subset of patients with chronic lymphocytic leukaemia and large local reactions to mosquito bites significantly induces upregulation of CD63 surface expression in atopic basophils. Pathology, 2016, 48, S57. | 0.6 | 0 |
| 86 | Exploring the mechanisms of large local reactions to insect bites in patients with chronic lymphocytic leukaemia. Pathology, 2016, 48, S43. | 0.6 | 0 |
| 87 | The therapeutic potential of dual inhibition of MEK1/2 and akt in chronic lymphocytic leukaemia (CLL). Pathology, 2017, 49, S110-S111. | 0.6 | 0 |
| 88 | A Novel Functional Assay Using Etoposide Plus Nutlin 3, FISH and Mutational Analysis Detects Heterogeneity of ATM/p53 Pathway Alterations in CLL.. Blood, 2006, 108, 2795-2795. | 1.4 | 0 |
| 89 | Defining the 10 Year Risk of Disease Progression in Stage A0 CLL.. Blood, 2006, 108, 2772-2772. | 1.4 | 0 |
| 90 | Epigenetic Regulation of ZAP70 in Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 2246-2246. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Inhibition of Mitogen Activated Protein Kinase Kinase (MEK1) Is Effective Against CLL Cells Cultured in Media Alone or in a Supportive Microenvironment and Is Synergistic with Fludarabine in a Mechanism That Involves Decreased Levels of Reactive Oxygen Species and MCL-1 Protein. Blood, 2012, 120, 1804-1804. | 1.4 | 0 |
| 92 | Molecular and Genetic Characterization of Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As Initial Treatment of Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 1959-1959. | 1.4 | 0 |
| 93 | Dual Inhibition of PIM and PI3-Kinase By Ibl-202 Is Highly Synergistic Compared to Mono-Molecular Inhibition and Represents a Novel Treatment Strategy for Chronic Lymphocytic Leukemia. Blood, 2014, 124, 4693-4693. | 1.4 | 0 |
| 94 | Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial. Blood, 2015, 126, 5295-5295. | 1.4 | 0 |
| 95 | The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53-Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment. Blood, 2018, 132, 1870-1870. | 1.4 | 0 |
| 96 | ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment. Blood, 2018, 132, 3145-3145. | 1.4 | 0 |
| 97 | Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy. Blood, 2018, 132, 3144-3144. | 1.4 | 0 |
| 98 | mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node. Blood, 2018, 132, 1850-1850. | 1.4 | 0 |
| 99 | Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status. Blood, 2018, 132, 4432-4432. | 1.4 | 0 |
| 100 | DNA Damage in Haemopoeitic Stem Cells Impacts on Neutrophil and Platelet Engraftment Following Autologous Transplantation. Blood, 2018, 132, 4622-4622. | 1.4 | 0 |
| 101 | TR57, an Inhibitor of the Integrated Stress Response, Is Synergistic with Venetoclax Against CLL Cells, Independent of Their TP53 Status. Blood, 2019, 134, 1735-1735. | 1.4 | 0 |
| 102 | Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia. , 2020, 3, 532-549. | | 0 |
| 103 | Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines. Nucleosides, Nucleotides and Nucleic Acids, 2022, 41, 314-320. | 1.1 | 0 |